About can fite biopharma ltd - CANF
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
CANF At a Glance
Can-Fite BioPharma Ltd.
26 Ben Gurion Street
Ramat Gan, 5257346
| Phone | 972-3-924-1114 | Revenue | 408.21K | |
| Industry | Pharmaceuticals: Major | Net Income | -9,905,965.35 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CANF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.074 |
| Price to Book Ratio | 0.937 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.517 |
| Enterprise Value to Sales | -12.673 |
| Total Debt to Enterprise Value | -0.014 |
CANF Efficiency
| Revenue/Employee | 81,642.572 |
| Income Per Employee | -1,981,193.071 |
| Receivables Turnover | 5.516 |
| Total Asset Turnover | 0.044 |
CANF Liquidity
| Current Ratio | 3.457 |
| Quick Ratio | 3.457 |
| Cash Ratio | 3.127 |
CANF Profitability
| Gross Margin | 94.074 |
| Operating Margin | -2,456.789 |
| Pretax Margin | -2,426.667 |
| Net Margin | -2,426.667 |
| Return on Assets | -106.322 |
| Return on Equity | -179.653 |
| Return on Total Capital | -174.927 |
| Return on Invested Capital | -178.584 |
CANF Capital Structure
| Total Debt to Total Equity | 1.27 |
| Total Debt to Total Capital | 1.254 |
| Total Debt to Total Assets | 0.746 |
| Long-Term Debt to Equity | 0.268 |
| Long-Term Debt to Total Capital | 0.265 |